The Cambridge, Massachusetts-based biotech could be the first iPSC-based cell therapy company to pursue multiple cell ...

The global cell therapy manufacturing market is poised for remarkable growth, with market size expected to reach USD 15,634.67 million by 2033, according to recent market projections. In 2023, the ...

Through TF-based cell fate programming, TFome is designed to yield first-in-class and best-in-class off-the-shelf cell therapy products up to 100 times more rapidly than conventional methods of cell ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

A drug production facility in Durham run by a Chinese company violated multiple safety regulations, according to the FDA. A ...

The EBMT is proud to announce that its Registry has achieved a landmark milestone of 10,000 chimeric antigen receptor T-cell (CAR-T) therapy patients. This significant achievement underscores the ...

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

Trailhead Biosystems Inc. announced Monday, Sept. 16, that it has hired Joshua Snow as chief commercial officer. The ...

About Neurona Therapeutics Neurona is developing allogeneic, off-the-shelf, regenerative neural cell therapy products with the potential to provide long-term targeted repair of the nervous system ...

CDMO collaboration propels cell replacement therapy targeting ... to enhance the effectiveness and cost-efficiency of cell therapy products. This collaboration exemplifies how combining cutting ...

While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, ...

NAD IV therapy is an effective and unique solution that is designed to address health and energy at the molecular level.